Drugs / VRP-HER2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03632941 | Mar 2019 → Sep 2023 | HER2 positive breast carcinoma | Herbert Lyerly | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRP-HER2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03632941 ↗ |
| Modality | Vaccine | “VRP-HER2 Vaccine 4 x 10EE8 IU given as a single injection every 2 weeks for 3 injections total” NCT03632941 ↗ |